Redcare Pharmacy continues to grow dynamically – share price on the verge of a breakthrough?

The online pharmaceutical retailer Redcare Pharmacy continued its dynamic growth trajectory in the second quarter of the current year. Management confirms all forecasts for the current fiscal year. The MDAX-listed share is expected to begin a strong countermovement after the sell-off of recent weeks.

In the second quarter, Redcare Pharmacy (formerly Shop Apotheke Europe) reported consolidated revenues of 26.4 percent to €709 million, precisely meeting market expectations. The company also further increased its active customer base by 0.4 million to 13.5 million.

While the business with over-the-counter products grew by 17 percent to 457 million euros, sales of prescription drugs climbed by a good 48 percent to 252 million euros (in Germany the increase was 125 percent in the second quarter).

Redcare Pharmacy also confirms its annual forecasts: sales are expected to increase by at least a quarter. The adjusted EBITDA margin is expected to be between 2.0 and 2.5 percent. The margin forecast, in particular, has recently been questionable, as it was only 1.3 percent in the first quarter.

"As for 2025, we are on track to meet all elements of our guidance. We expect our EBITDA margin to exceed 2% in the second quarter and improve further in the second half of the year," said Redcare CFO Jasper Eenhorst.